Cempra to Report Fourth Quarter and Full Year 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cempra to Report Fourth Quarter and Full Year 2014 Financial Results

CHAPEL HILL, N.C., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq: CEMP ), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it will report fourth quarter and full year 2014 financial results after the close of U.S. financial markets on February 25, 2015. Cempra management will host a webcast and conference call at 4:30 p.m. EST that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 877-377-7553 for domestic callers and 253-237-1151 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at www.cempra.com and will be archived there for 30 days. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 84387759.

About Cempra, Inc.

Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) is in Phase 3 clinical development for community acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin also recently entered a Phase 3 clinical trial for uncomplicated bacterial urethritis caused by Neisseria gonorrhoeae and chlamydia. Taksta™ (CEM-102) is Cempra's second product candidate, which is being developed for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com .

Investor Contact: Robert H. Uhl Westwicke Partners, LLC (858) 356-5932 Media Contact: Robert E. Flamm, Ph.D. Russo Partners, LLC (212) 845-4226

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rural Hospitals Face Shaky Future; Warbird RCM Steps In

Updated Category News Views 3

Revamping Revenue Cycle Management for Rural Healthcare In a world that's increasingly teetering on the delicate tightrope of balance sheets, Warbird Healthcare Advisors is stepping into the ring with fists up, ready to fight for rural hospitals. Introducing their latest venture, Warbird RCM Partners, they're honing in on revenue cycle management and billing services to...

Continue Reading
When Families Should Consider Life Insurance Plans

Updated Category News Views 4

Let’s talk about why life insurance isn’t just for those walking around with gray hair. K.D. the Insurance Queen from Centennial, Colorado, dishes out the clearest advice on when and why families ought to have it in their arsenal. A New Mindset on Life Insurance Some folks out there think life insurance is something you ponder in your twilight years. But here’s the...

Continue Reading
Critical Questions to Ask When Buying Life Insurance

Updated Category News Views 3

Getting Under the Hood of Life Insurance Alright, so you're thinking about life insurance. Not exactly a day at the beach, but it’s one of those crucial life things to nail down. Paula Miller, a savvy insurance pro, walks through what to consider before you just slap down a signature and hope for the best. The Basics: Policy Types and Coverage Life insurance can be as...

Continue Reading
Centrus Energy to Discuss Q3 Earnings on Nov 5 Call

Updated Category News Views 7

Centrus Energy Prepares for Earnings Call You ever feel that twinge in your gut right before a big disclosure? Well, that's where Centrus Energy’s about to take us as they gear up for their quarterly earnings call. On November 5th, bright and early at 8:30 a.m. Eastern Time, NYSE:LEU will be in the spotlight, laying out its Q3 results for all us nose-to-the-grindstone...

Continue Reading
Ellington's Q3 Earnings Call: What Investors Need to Know

Updated Category News Views 5

An Anticipated Unveiling Ellington Financial Inc. (NYSE:EFC) is gearing up to spill the beans on its third-quarter financials for 2026. It's all going down after the markets close on November 4th. I can tell you, folks, anyone keeping an eye on EFC will be itching to know what's inside those numbers. With a company this deep into financial assets, reading between the...

Continue Reading
Podium Surges Past $150M in AI ARR Milestone

Updated Category News Views 8

A New Era for Podium When the brass at Podium made a gamble on AI, they didn't just try squeezing it into their old business model. Oh no, they launched what feels like a startup within their existing empire—no half-measures, just full-throttle ambition. Fast forward two and a half years, and they've racked up over $150 million in annual recurring revenue from these...

Continue Reading
Harbour BioMed's Batoclimab Injected Into Myasthenia Market

Updated Category News Views 5

China's Green Light for Batoclimab When a new drug approval hits, particularly in a crucial market like China, it's a big deal. Harbour BioMed's recent go-ahead from the National Medical Products Administration (NMPA) for their Batoclimab injection is no exception. This marks the first full clinical cycle completion of an anti-FcRn treatment for generalized myasthenia...

Continue Reading
Gillis Joins McGinnis Lochridge as COO Amid Firm's Milestone

Updated Category News Views 6

An Experienced Executor at the Helm Now, here's a story that rings of continuity meeting change. McGinnis Lochridge, a staple of the Texas legal scene since 1927, has tapped Charles Gillis to take charge as their Chief Operating Officer. You'd think they're gearing up to celebrate a hundred years by shaking things up internally. Why not bring in someone seasoned, I say?...

Continue Reading
Dott's Q3 2026: Micromobility Growth Soars High

Updated Category News Views 5

Riding the Wave of Profit in Micromobility Sometimes all you need is a quick jolt of genius to turn the wheels of fortune. Dott seems to have hit that sweet spot in Q3 of 2026. Deploying 45,000 new vehicles wasn’t just a logistical feat; it was a calculated bet that paid off handsomely, bolstering their business to soaring heights. Performance that Packs a Punch The Q3...

Continue Reading
NYC's Carriage Horse Ban: A New Era for Urban Welfare

Updated Category News Views 4

You've got to hand it to New York City—this isn't just another Tuesday twist. The City Council's decision to nix horse-drawn carriages is like throwing a wrench in an antique machine. It's a bold move in a concrete jungle that's constantly wearing new coats. Tradition vs. Welfare: The Crux For years, the idea of horses prancing down NYC streets seemed like a quaint nod...

Continue Reading

Top 5 Most Recently Viewed Articles

KBR Secures $85 Million Contract for Essential Airfield Supplies

Updated Category News Views 252

KBR Secures Major Contract for Airfield Repair Solutions KBR (NYSE: KBR) has proudly announced that it has clinched a firm fixed-price contract worth $85 million with the U.S. Air Force. This contract focuses on the procurement, design, and delivery of essential training aids along with airfield damage repair kits around the globe. This operational venture falls under the...

Continue Reading
Medianet Unveils Comprehensive Platform for Media Intelligence

Updated Category News Views 138

Medianet got ready to launch its innovative media intelligence platform back in 2024, aiming to integrate various media services into a single seamless experience. This isn't just some run-of-the-mill upgrade; this is the kind of game-changer that could rattle competitors who’ve grown too comfortable in their foreign-owned thrones. Game-Changer Alert: Medianet’s...

Continue Reading
Visa Set to Reveal Q1 2025 Financials on January 30

Updated Category News Views 174

Visa Set to Announce Fiscal Q1 2025 Financial Results Visa (NYSE: V) is preparing to unveil its financial results for the first quarter of fiscal 2025. This much-anticipated announcement will take place on January 30, 2025, following the market’s closure. As per tradition, the company will file the details with the Securities and Exchange Commission and will provide the...

Continue Reading
EHang's Upcoming Financial Results and Innovations in Air Mobility

Updated Category News Views 171

EHang Holdings Limited Set to Announce Financial Results GUANGZHOU, China — EHang Holdings Limited (Nasdaq: EH), renowned for its pioneering Urban Air Mobility (UAM) technology, is preparing to unveil its financial results for the second quarter. Conference Call Details The company's earnings announcement is scheduled for Tuesday, ahead of the U.S. market opening. This...

Continue Reading
Real Estate Sales Trends: What August's Data Revealed

Updated Category News Views 221

Understanding August's Existing-Home Sales Trends Recent reports indicate that existing-home sales in August showed a slight decline of 0.2% compared to July. This data highlights the evolving landscape of the real estate market. The National Association of REALTORS® (NAR) provided insights into the current conditions affecting homebuyers and sellers, including...

Continue Reading
ection End -->